Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15237486 | 1.00 | CYP2C19 (0.54) | CYP2C19CYP1A2USP2ALDH1A1LMNA | |
| SCHEMBL6914857 | 0.98 | CYP2C19 (0.52) | CYP2C19CYP1A2USP2ALDH1A1LMNA | |
| SCHEMBL6908133 | 0.98 | CYP2C19 (0.52) | CYP2C19CYP1A2USP2ALDH1A1LMNA | |
| SCHEMBL6918554 | 0.98 | CYP2C19 (0.52) | CYP2C19CYP1A2USP2ALDH1A1LMNA | |
| SCHEMBL6916767 | 0.98 | CYP2C19 (0.52) | CYP2C19CYP1A2USP2ALDH1A1LMNA | |
| SCHEMBL6914937 | 0.98 | CYP2C19 (0.52) | CYP2C19CYP1A2USP2ALDH1A1LMNA | |
| SCHEMBL6913148 | 0.98 | CYP2C19 (0.52) | CYP2C19CYP1A2USP2ALDH1A1LMNA | |
| SCHEMBL6909533 | 0.98 | CYP2C19 (0.52) | CYP2C19CYP1A2USP2ALDH1A1LMNA | |
| SCHEMBL6914861 | 0.98 | CYP2C19 (0.52) | CYP2C19CYP1A2USP2ALDH1A1LMNA | |
| SCHEMBL1480296 | 0.97 | CYP2C19 (0.50) | CYP2C19CYP1A2USP2ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 304 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114790136-A | Preparation method and application of active trivalent organic chromium compound | 中国石油天然气股份有限公司 | 2022-07-26 | — | — | CN | claimed |
| US-20190016745-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2019-01-17 | — | — | US | claimed |
| EP-3400231-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS | Technion Research & Development Foundation Limited (IL) | 2018-11-14 | — | — | EP | claimed |
| US-20180282361-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | ELOXX PHARMACEUTICALS LTD. (IL) | 2018-10-04 | — | — | US | claimed |
| EP-3344641-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | Eloxx Pharmaceuticals Ltd. (IL) | 2018-07-11 | — | — | EP | claimed |
| WO-2017118967-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LIMITED (IL) | 2017-07-13 | — | — | WO | claimed |
| WO-2017037719-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | ELOXX PHARMACEUTICALS LTD. (IL) | 2017-03-09 | — | — | WO | claimed |
| EP-2118052-A2 | NOVEL PRODRUGS | Sun Pharma Advanced Research Company Ltd (IN) | 2009-11-18 | — | — | EP | claimed |
| WO-2008111096-A2 | NOVEL PRODRUGS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2008-09-18 | — | — | WO | claimed |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2003-04-03 | — | — | US | claimed |
| US-12459882-B2 | Process for preparing 1,2-propanediol from propane | EVONIK OPERATIONS GMBH (DE) | 2025-11-04 | — | — | US | disclosed |
| EP-4337603-B1 | OPTIMIZED STEAM NETWORK FOR THE AO PROCESS | EVONIK OPERATIONS GMBH (DE) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| EP-4337645-B1 | AN INTEGRATED PLANT AND AN INTEGRATED PROCESS FOR MAKING PROPENE OXIDE | EVONIK OPERATIONS GMBH (DE) | 2025-03-12 | — | — | EP | disclosed |
| US-12102648-B2 | Orally-bioavailable nucleoside analogs | VenatoRx Pharmaceuticals, Inc. (US) | 2024-10-01 | — | — | US | disclosed |
| US-3984393-A | BACTERICIDES | THE UPJOHN COMPANY (US) | 1976-10-05 | — | — | US | disclosed |
| US-3976667-A | ANTIBIOTIC | THE UPJOHN COMPANY (US) | 1976-08-24 | — | — | US | disclosed |
| US-3960762-A | Production of absorbents | BAYER AKTIENGESELLSCHAFT (DT) | 1976-06-01 | — | — | US | disclosed |
| US-3945831-A | Photosensitive resins containing a thienylacrylic acid ester or amide group | FUJI PHOTO FILM CO., LTD. (JA) | 1976-03-23 | — | — | US | disclosed |
| US-3944562-A | ANTIBIOTIC | THE UPJOHN COMPANY (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12102648-B2 | Orally-bioavailable nucleoside analogs | SLC29A2, SLC29A1, PNP | CYP2C19 206/4885CYP1A2 387/4885USP2 2695/4885 |
| US-20190016745-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING MICROBIAL INFECTIONS | ALPI, MGAM, AASDHPPT | CYP2C19 902/4885CYP1A2 986/4885USP2 4664/4885 |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | CYP2C19 775/4885CYP1A2 254/4885USP2 860/4885 |
| US-20180282361-A1 | AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF IN TREATING GENETIC DISORDERS | UPF1, AARS1, NUDT21 | CYP2C19 2439/4885CYP1A2 2733/4885USP2 4425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.